Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
The notice of meeting is available on Cellectis’ investor website.
Details
News Market Reaction – CLLS
On May 21, the first trading day after this news, CLLS closed 3.83% below the previous close. That session’s volume was 1.6x the stock’s average daily volume.
Data tracked by StockTitan Argus for the May 21 session.
Key Figures
- AGM date
- June 25, 2026
- Scheduled annual general meeting
- AGM time
- 2:30 p.m. CET
- Scheduled annual general meeting start time
- AGM venue street number
- 11 rue Watt
- Biopark auditorium address in Paris
- AGM venue floor
- 4th floor
- Biopark auditorium floor location
- Postal code
- 75013
- Paris postal code for AGM venue
Historical Context
-
Announced upcoming lasme‑cel and eti‑cel clinical data at EHA 2026.
-
Reported first quarter 2026 financial results to investors.
-
Published monthly statement of share capital and voting rights.
-
Announced timing for release of Q1 2026 financial results.
-
Presented TALE-based epigenetic editing platform data at ASGCT meeting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
gene-editing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
The notice of meeting is available on the Cellectis website: https://www.cellectis.com/en/investors/general-meetings/
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.